Table 4.

Medication for the treatment of Lung Cancer for which adverse cardiovascular effects are most frequent.

Class	Drug	Adverse cardiovascular effects
Platins	General	Arrhythmias, myocardial ischemia, AHT
	Cisplatin	HypoMg, HypoK, due to nephrotoxicity
Antimicrotubule	Paclitaxel	Bradycardia, other arrhythmias
	Vinca alkaloids	AHT, myocardial ischemia and infarction
Angiogenesis inhibitors	Bevacizumab	AHT, HF, ischemia, arterial thrombosis
	Ramucirumab	AHT, arterial thrombosis, ischemia, HF
EGFR inhibitors	General	Reduction in LVEF
	Necitumumab	Arrhythmias and DVT
	Osimertinib	Long QT syndrome
	Afatinib	Focus on LVEF in heart disease patients
ALK inhibitors	Crizotinib	Bradycardia, long QT syndrome and pulmonary embolism
	Ceritinib	Bradycardia, long QT syndrome, pericarditis and AHT
	Brigatinib	AHT
Immunotherapy	General	Myocarditis, pericarditis, arrhythmias

AHT: arterial hypertension; HF: heart failure; LVEF: left ventricular ejection fraction; DVT: deep vein thrombosis.

Modified from reference number.¹⁸³